HR+/HER2-negative Breast Cancer
3 clinical trials · Condition
◉ Watch HR+/HER2-negative Breast Cancer
| Record | Firm | Date |
|---|---|---|
| A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer (NCT03560856) | Assistance Publique - Hôpitaux de Paris | 2018-06-27 |
Track HR+/HER2-negative Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.